rs151344631
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PP3_ModeratePP5_Very_Strong
The NM_000218.3(KCNQ1):c.613G>A(p.Val205Met) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000744 in 1,613,162 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0000048 ( 0 hom. )
Consequence
KCNQ1
NM_000218.3 missense
NM_000218.3 missense
Scores
12
6
1
Clinical Significance
Conservation
PhyloP100: 7.36
Genes affected
KCNQ1 (HGNC:6294): (potassium voltage-gated channel subfamily Q member 1) This gene encodes a voltage-gated potassium channel required for repolarization phase of the cardiac action potential. This protein can form heteromultimers with two other potassium channel proteins, KCNE1 and KCNE3. Mutations in this gene are associated with hereditary long QT syndrome 1 (also known as Romano-Ward syndrome), Jervell and Lange-Nielsen syndrome, and familial atrial fibrillation. This gene exhibits tissue-specific imprinting, with preferential expression from the maternal allele in some tissues, and biallelic expression in others. This gene is located in a region of chromosome 11 amongst other imprinted genes that are associated with Beckwith-Wiedemann syndrome (BWS), and itself has been shown to be disrupted by chromosomal rearrangements in patients with BWS. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Aug 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.913
PP5
Variant 11-2571333-G-A is Pathogenic according to our data. Variant chr11-2571333-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 37255.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-2571333-G-A is described in Lovd as [Pathogenic]. Variant chr11-2571333-G-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KCNQ1 | NM_000218.3 | c.613G>A | p.Val205Met | missense_variant | 4/16 | ENST00000155840.12 | NP_000209.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KCNQ1 | ENST00000155840.12 | c.613G>A | p.Val205Met | missense_variant | 4/16 | 1 | NM_000218.3 | ENSP00000155840.2 | ||
KCNQ1 | ENST00000335475.6 | c.232G>A | p.Val78Met | missense_variant | 4/16 | 1 | ENSP00000334497.5 | |||
KCNQ1 | ENST00000496887.7 | c.352G>A | p.Val118Met | missense_variant | 5/16 | 5 | ENSP00000434560.2 | |||
KCNQ1 | ENST00000646564.2 | c.478-12102G>A | intron_variant | ENSP00000495806.2 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152152Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
5
AN:
152152
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000798 AC: 2AN: 250528Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135708
GnomAD3 exomes
AF:
AC:
2
AN:
250528
Hom.:
AF XY:
AC XY:
0
AN XY:
135708
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461010Hom.: 0 Cov.: 32 AF XY: 0.00000413 AC XY: 3AN XY: 726838
GnomAD4 exome
AF:
AC:
7
AN:
1461010
Hom.:
Cov.:
32
AF XY:
AC XY:
3
AN XY:
726838
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152152Hom.: 0 Cov.: 33 AF XY: 0.0000404 AC XY: 3AN XY: 74312
GnomAD4 genome
AF:
AC:
5
AN:
152152
Hom.:
Cov.:
33
AF XY:
AC XY:
3
AN XY:
74312
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
1
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Long QT syndrome 1 Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 01, 2008 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Mar 02, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genomics Laboratory, Washington University in St. Louis | Sep 04, 2023 | The KCNQ1 c.613G>A (p.Val205Met) variant has been reported in the medical literature in individuals affected with long QT syndrome (Arbour L et al., PMID: 18580685; Eldstrom J et al., PMID: 25444851; Jackson H et al., PMID: 23844633; Natarajan P et al., PMID: 27831900). This variant is only observed on 3/281,894 total alleles in the general population (gnomAD v.2.1.1), indicating it is not a common variant. Computational predictors indicate that the variant is damaging, evidence that correlates with impact to KCNQ1 protein function. Functional studies suggest that this variant reduces KCNQ1 channel activity, indicating impact to protein function (Arbour L et al., PMID: 18580685; Eldstrom J et al., PMID: 25444851). This variant has been submitted to ClinVar as pathogenic by seven laboratories (variation ID: 37255). Based on available information, and based on ACMG/AMP guidelines for variant interpretation (Richards S et al., PMID: 25741868), this variant is classified as pathogenic. - |
Long QT syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 16, 2023 | For these reasons, this variant has been classified as Pathogenic. This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 205 of the KCNQ1 protein (p.Val205Met). This variant is present in population databases (rs151344631, gnomAD 0.008%). This missense change has been observed in individuals with long QT syndrome in members of First Nation communities in British Columbia. It has been observed in the heterozygous and homozygous state in numerous affected individuals, though the severity of the symptoms was variable. In addition, this variant has been observed in unrelated individuals with long QT syndrome (PMID: 18580685, 23844633, 26669661, 27831900). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 37255). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt KCNQ1 protein function. Experimental studies have shown that this missense change affects KCNQ1 function (PMID: 18580685, 25444851). - |
Pathogenic, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 31, 2018 | Variant summary: KCNQ1 c.613G>A (p.Val205Met) results in a conservative amino acid change located in the Ion transport domain (IPR005821) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.1e-05 in 276590 control chromosomes. c.613G>A has been reported in the literature in multiple heterozygous individuals of whom several were affected with Long QT syndrome, as well as in four homozygous patients presenting with a more severe cardiac phenotype, and occasionally with symptoms suggestive of Jervell and Lange-Nielsen syndrome (Jackson 2014). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Arbour 2008). The most pronounced variant effect results in approximately 30%-50% of the normal channel activity. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:2Other:1
not provided, no classification provided | literature only | Community Genetics, University of British Columbia | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 10, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies demonstrate marked alteration of channel activity (Arbour et al., 2008; Eldstrom et al., 2010; Eldstrom et al., 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25637381, 22378279, 18580685, 20421371, 25525159, 23844633, 31447099, 31589614, 31737537, 28264985, 34319147, 27831900, 25444851, Sanatani2022[Article], RidaM2023[Preprint], 26669661, 32009526, 36725074) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2024 | KCNQ1: PP1:Strong, PM1, PS3:Moderate, PS4:Moderate, PM2:Supporting, PP3 - |
Congenital long QT syndrome Pathogenic:1Other:1
not provided, no classification provided | literature only | Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust | - | This variant has been reported as associated with Long QT syndrome in the following publications (PMID:18580685;PMID:20421371;PMID:22378279). This is a literature report, and does not necessarily reflect the clinical interpretation of the Imperial College / Royal Brompton Cardiovascular Genetics laboratory. - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 07, 2017 | The p.Val205Met variant in KCNQ1 has been reported in 2 individuals with long QT syndrome and segregated with disease in at least 10 affected relatives from bot h families (Arbour 2008). Additionally, four individuals have been reported to b e homozygous for this variant and present with a clinically more severe phenotyp e that did not include hearing loss (Jackson 2014). This variant has also been r eported by other clinical laboratories in ClinVar (variation ID: 3725) and has b een identified in 1/126300 European chromosomes by the Genome Aggregation Databa se (gnomAD, http://gnomad.broadinstitute.org/; dbSNP rs151344631). In vitro func tional studies provide evidence that the p.Val205Met variant may impact protein function (Arbour 2008, Eldstrom 2010, Eldstrom 2015). In summary, this variant m eets criteria to be classified as pathogenic for long QT syndrome in an autosoma l dominant manner based upon segregation studies and functional evidence. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 05, 2017 | The p.V205M pathogenic mutation (also known as c.613G>A), located in coding exon 4 of the KCNQ1 gene, results from a G to A substitution at nucleotide position 613. The valine at codon 205 is replaced by methionine, an amino acid with highly similar properties. This mutation has been reported in multiple families with long QT syndrome and has been observed with an elevated prevalence in an isolated Northern Canadian population (Arbour L, Genet. Med. 2008 Jul; 10(7):545-50; Kapplinger JD et al. J. Med. Genet., 2017 Mar; Pottinger TD et al. J Am Heart Assoc, 2020 Feb;9:e013808). Additionally, in vitro studies have shown this mutant exhibits altered channel gating kinetics and currents in transfected cells (Arbour L et al. Genet. Med., 2008 Jul;10:545-50; Jackson HA, Clin. Genet. 2014 Jul; 86(1):85-90; Eldstrom J, Heart Rhythm 2015 Feb; 12(2):386-94). Based on the supporting evidence, p.V205M is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
.;D;.
Eigen
Pathogenic
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
.;M;.
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;D;N
REVEL
Pathogenic
Sift
Uncertain
D;D;D
Sift4G
Uncertain
D;D;D
Polyphen
1.0
.;D;.
Vest4
0.92, 0.90
MVP
MPC
1.2
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at